Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) congress, as they ...

asthma and chronic obstructive pulmonary disease (COPD). Sanofi reported in its Q4 2024 results that Dupixent surpassed its €13bn ($13.6bn) sales target for the full year, reaching $14.15bn sales.

As the UK endures another harsh winter, plummeting temperatures and a surge in respiratory infections are placing strain on ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Sanofi’s SNY stock has declined 10.2% in ... prurigo nodularis and chronic obstructive pulmonary disease (COPD). Dupixent is now annualizing at close to €11.0 billion in sales after almost ...

Mental health disorders in people with chronic obstructive pulmonary disease (COPD) are underdiagnosed and undertreated, leading to worsened symptoms and decreased quality of life, according to a new ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ... chronic spontaneous urticaria (CSU), and chronic obstructive pulmonary disease (COPD) in different age populations.